Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

被引:29
|
作者
Aasen, Synnove Nymark [1 ,2 ]
Parajuli, Himalaya [1 ]
Tuyen Hoang [1 ]
Feng, Zichao [1 ,3 ]
Stokke, Krister [1 ]
Wang, Jiwei [1 ,3 ]
Roy, Kislay [1 ]
Bjerkvig, Rolf [1 ,4 ]
Knappskog, Stian [2 ,5 ]
Thorsen, Frits [1 ,4 ,6 ]
机构
[1] Univ Bergen, Kristian Gerhard Jebsen Brain Tumour Res Ctr, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway
[2] Haukeland Hosp, Dept Oncol & Med Phys, Jonas Lies Vei 65, N-5021 Bergen, Norway
[3] Shandong Univ, Brain Sci Res Inst, 44 Wenhuaxi Rd, Jinan 250100, Shandong, Peoples R China
[4] Luxembourg Inst Hlth, Dept Oncol, NorLux Neurooncol Lab, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg
[5] Univ Bergen, Sect Oncol, Dept Clin Sci, N-5020 Bergen, Norway
[6] Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway
关键词
melanoma; brain metastasis; BRAF; MAPK; PI3K; combined treatment; apoptosis; CANCER CELLS; ACQUIRED-RESISTANCE; BUPARLISIB BKM120; BRAIN METASTASIS; DOSE-ESCALATION; IN-VITRO; MEK; APOPTOSIS; EXPRESSION; SURVIVIN;
D O I
10.3390/ijms20174235
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant melanoma is the most aggressive type of skin cancer and is closely associated with the development of brain metastases. Despite aggressive treatment, the prognosis has traditionally been poor, necessitating improved therapies. In melanoma, the mitogen activated protein kinase and the phosphoinositide 3-kinase signaling pathways are commonly altered, and therapeutically inhibiting one of the pathways often upregulates the other, leading to resistance. Thus, combined treatment targeting both pathways is a promising strategy to overcome this. Here, we studied the in vitro and in vivo effects of the PI3K inhibitor buparlisib and the MEK1/2 inhibitor trametinib, used either as targeted monotherapies or in combination, on patient-derived melanoma brain metastasis cell lines. Scratch wound and trans-well assays were carried out to assess the migratory capacity of the cells upon drug treatment, whereas flow cytometry, apoptosis array and Western blots were used to study apoptosis. Finally, an in vivo treatment experiment was carried out on NOD/SCID mice. We show that combined therapy was more effective than monotherapy. Combined treatment also more effectively increased apoptosis, and inhibited tumor growth in vivo. This suggests a clinical potential of combined treatment to overcome ceased treatment activity which is often seen after monotherapies, and strongly encourages the evaluation of the treatment strategy on melanoma patients with brain metastases.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma
    Fowles, J. S.
    Denton, C. L.
    Gustafson, D. L.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2015, 13 (03) : 288 - 304
  • [22] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [23] PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations
    Janku, Filip
    Broaddus, Russell
    Bakkar, Rania
    Hong, David S.
    Stepanek, Vanda M. T.
    Naing, Aung
    Falchook, Gerald Steven
    Fu, Siqing
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Moulder, Stacy L.
    Luthra, Rajyalakshmi
    Tsimberidou, Apostolia Maria
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] A model study of coupled MAPK and PI3K signaling pathways
    Hu, DW
    Yuan, JM
    BIOPHYSICAL JOURNAL, 2004, 86 (01) : 450A - 450A
  • [25] MAPK and PI3K signaling: At the crossroads of neural crest development
    Dinsmore, Colin J.
    Soriano, Philippe
    DEVELOPMENTAL BIOLOGY, 2018, 444 : S79 - S97
  • [26] Kinetic analysis of the MAPK and PI3K/Akt signaling pathways
    Suresh, Babu C., V
    Babar, Sheikh Md. Enayetul
    Song, Eun Joo
    Oh, Eulsik
    Yoo, Young Sook
    MOLECULES AND CELLS, 2008, 25 (03) : 397 - 406
  • [27] Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
    Ciuffreda, Ludovica
    Incani, Ursula Cesta
    Steelman, Linda S.
    Abrams, Stephen L.
    Falcone, Italia
    Del Curatolo, Anais
    Chappell, William H.
    Franklin, Richard A.
    Vari, Sabrina
    Cognetti, Francesco
    McCubrey, James A.
    Milella, Michele
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (24) : 3944 - 3957
  • [28] Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
    Williams, Terence M.
    Flecha, Athena R.
    Keller, Paul
    Ram, Ashwin
    Karnak, David
    Galban, Stefanie
    Galban, Craig J.
    Ross, Brian D.
    Lawrence, Theodore S.
    Rehemtulla, Alnawaz
    Sebolt-Leopold, Judith
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (05) : 1193 - 1202
  • [29] Effects of various MAPK and PI3K/Akt inhibitors on the constitutive secretion of VEGF by uveal melanoma cells
    Hu, Dan-Ning
    McCormick, Steven A.
    Vagaggini, Tommaso
    Rosen, Richard B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [30] PI3K Pathway Inhibitors: Better Not Left Alone
    Markman, Ben
    Tao, Jessica J.
    Scaltriti, Maurizio
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (05) : 895 - 906